Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Accumulated Expenses (2020 - 2025)

Maxcyte (MXCT) has disclosed Accumulated Expenses for 6 consecutive years, with $7.8 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 5.9% to $7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Dec 2025, down 5.9% year-over-year, with the annual reading at $7.8 million for FY2025, 5.9% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $7.8 million at Maxcyte, down from $8.3 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $11.3 million in Q4 2023, with the low at $3.9 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $7.2 million, with a median of $7.1 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses surged 78.59% in 2023, then fell 26.33% in 2024.
  • Over 5 years, Accumulated Expenses stood at $6.5 million in 2021, then rose by 26.7% to $8.3 million in 2022, then soared by 36.35% to $11.3 million in 2023, then dropped by 26.33% to $8.3 million in 2024, then decreased by 5.9% to $7.8 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $7.8 million, $8.3 million, and $6.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.